ADVERTISEMENT
News
Chemotherapy Medication Recalled
12/03/2020
The recall affects doxorubicin hydrochloride injection, 10 mg/5 mL (2 mg/mL), 5-mL fill in a 6-mL vial (NDC 63323-883-05), from batch 6120525 (Exp. 11/20). The product was distributed throughout the United States and Puerto Rico.
Fresenius Kabi voluntarily initiated the recall November 17, 2020. On November 24, 2020, the FDA designated the recall Class III. Under the recall classification, use of the affected product is not likely to cause harm.
Doxorubicin hydrochloride injection is a prescription chemotherapy medication used to treat cancer.
—Jolynn Tumolo
Stay Informed & Sign Up Today
Pharmacy Learning Network Newsletter
